SAN DIEGO, Calif. and NES-ZIONA, Israel, April 24, 2013 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP are investigating the acquisition of PROLOR Biotech, Inc. (NYSE MKT: PBTH) by OPKO Health, Inc. (NYSE: OPK). On April 24, 2013, PROLOR and OPKO announced the signing of a definitive merger agreement whereby PROLOR shareholders will receive 0.9951 shares of OPKO common stock for each share of PROLOR common stock owned, a value of approximately $7.00 per PROLOR share. The transaction is expected to close during the second half of 2013.
The Board of Director's Actions May Prevent PROLOR Shareholders from Receiving Maximum Value for Their Stock
Robbins Arroyo LLP's investigation focuses on whether the board of directors at PROLOR is undertaking a fair process to obtain maximum value and adequately compensate its shareholders in the merger or whether they are seeking to benefit themselves. Notably, Dr. Philip Frost is both Chairman of the Board of PROLOR and CEO and the Chairman of OPKO. Given this fact, the firm is investigating whether the merger was motivated by conflicts of interest in light of Dr. Frost's significant position in both companies.Is the Acquisition Best for PROLOR and Its Shareholders? Moreover, PROLOR is currently in the process of developing multiple products, all of which could lead to be very financially successful for the company. Specifically, PROLOR's Human Growth Hormone, used for the long-term treatment of children and adults with growth failure, is scheduled for Phase III trials and has a claimed potential market opportunity of $3 billion. Further, PROLOR also has two products currently in Phase I testing, both of which have claimed potential market opportunities of $2 billion: GLP-1, used in the treatment for Type II Diabetes which is believed to have a dramatically better weight-loss profile than GLP-1 therapies currently available, and Factor VIIa and Factor IX, both used in the treatment of Hemophilia. The firm is examining the board of directors' decision to sell PROLOR now rather than allow shareholders to continue to participate in the company's continued success and future growth prospects.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV